+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Human placenta tissue, Primary antibody: P12502(CLDN25 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P12502(CLDN25 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

Claudin-25 (CLDN25) is a member of the claudin family, a group of transmembrane proteins critical for forming tight junctions that regulate paracellular permeability and maintain cellular polarity. Though less studied than other claudins (e.g., CLDN18.2 or CLDN1), CLDN25 is structurally characterized by its four transmembrane domains and extracellular loops, which mediate cell-cell adhesion. Emerging research suggests its potential role in tissue-specific barrier functions, particularly in organs like the gastrointestinal tract or kidneys.

CLDN25 has drawn interest in biomedical research due to its aberrant expression in certain cancers. For instance, studies indicate its upregulation in gastrointestinal malignancies, where it may contribute to tumor progression or metastasis by altering cell adhesion and signaling pathways. Antibodies targeting CLDN25 are being explored as tools for mechanistic studies, diagnostic markers, or therapeutic agents. However, research remains limited compared to other claudins, partly due to its low baseline expression in normal tissues and challenges in developing specific antibodies.

Current efforts focus on validating CLDN25's functional roles and clinical relevance. Therapeutic antibodies against CLDN25 could theoretically disrupt cancer-specific tight junctions or enable targeted drug delivery, but challenges like off-target effects and heterogeneous tumor expression require further investigation. Overall, CLDN25 represents a niche yet promising target in tight junction biology and oncology.